{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-116477","form_type":"8-K","ticker":"RZLT","cik":"0001509261","company_name":"Rezolute, Inc.","filed_at":"2022-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.918515+00:00","generated_at":"2026-06-22T01:10:27.026873+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Rezolute Q1 FY2023 net loss $9.8M; cash $154.3M; RZ358/402 advance","bullets":["Cash and equivalents $154.3M as of Sep 30, 2022; net loss $9.8M vs $7.8M YoY.","R&D expenses $7.7M (up 33% YoY); G&A $2.5M (up 32% YoY) on higher clinical and stock-based costs.","RZ358 Phase 2b showed ~75% reduction in hypoglycemia events; regulatory discussions underway for Phase 3.","RZ402 Phase 1b MAD data supports once-daily dosing; Phase 2 proof-of-concept study expected by end-2022.","Closed $130M financing post-quarter to advance both molecules into next clinical stages."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-116477","json":"https://secwatch.observer/filing/0001104659-22-116477.json","markdown":"https://secwatch.observer/filing/0001104659-22-116477.md","text":"https://secwatch.observer/filing/0001104659-22-116477.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1509261/000110465922116477/0001104659-22-116477-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1509261/000110465922116477/tm2230110d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T01:10:27.026873+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e006547712db585418802c9403f887fb2a73fd14","claim":"Rezolute, Inc. reported the first quarter of fiscal 2023 ended September 30, 2022 results: net income Net loss was $9.8 million for the first quarter of fiscal 2023.","evidence_excerpt":"Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential to shift the treatment paradigms of devastating metabolic diseases, today announced its financial results for the first quarter of fiscal 2023 ended September 30, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1509261/000110465922116477/0001104659-22-116477-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter of fiscal 2023 ended September 30, 2022"},{"label":"Net income","value":"Net loss was $9.8 million for the first quarter of fiscal 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}